Geneuro Innovation SAS

Geneuro Innovation SAS est membre de Lyonbiopôle

General information

60 avenue de Rockefeller

69008 Lyon

Incorporated in: 2009/02/18

Number of employees: 15

Turnover: €1M (in 2017)


More information

 

Main activity

Geneuro is a product development company, developing a pioneering approach for the therapy of diseases associated with human endogeneous retrovirus expression, with a primary focus on nervous system diseases. Geneuro anticipates the first clinical trial of its monoclonal antibody early 2011 in multiple sclerosis and also carries out extensive preclinical research in other diseases such as schizophrenia. Geneuro breakthrough innovation targets the envelope protein of human endegeneous retrovirus. Its lead product, a monoclonal antibody, acts upstream of the pro-inflammatory cascade, thus increasing efficacy and safety over existing drugs which mainly delay neurological damages and disability caused by Multiple sclerosis. Geneuro is driven by entrepreneurial spirit and supported by a well established network of worldwide leading industrial and academic partners.


Funding

Public funding obtained: No

Segmentation
Activities
Products / Services / Technologies
Partnership opportunities / Licensing

Strategic area of application
Human Medicine


Application market
Immune, AutoIm & Inflam. diseases - Neurological diseases


Activities
Therapeutics, Pharma or Biotech


Technologies
Antibodies - Protein - Peptide

En poursuivant votre navigation sur notre site, vous acceptez l'utilisation des cookies et la collecte de vos données et informations personnelles par Lyonbiopôle, dans les finalités de mesurer le trafic sur le site Web, de fournir des statistiques et de vous proposer des contenus adaptés à vos centres d’intérets. Pour exercer vos droits d'accès, de rectification, d'opposition, de suppression et de portabilité, conformément au règlement général sur la protection des données (UE n°2016/679), vous etes informés que vous pouvez envoyer votre demande à dpo@lyonbiopole.com. Plus de détails sont disponibles en cliquant ici J'accepte